

Acute Coronary Syndrome in HIV Naïve Patient with Low CD4 Count and No Other Significant Risk Factors: Case Report and Literature Review.

Zaher Fanari, MD

Section of Cardiology, Christiana Care Health System, 4755 Ogletown-Stanton Rd., Newark, DE 19718, USA

Tel: +1 (314) 808-1610; Fax: +1 (302) 733-4998; Email: zfanari@gmail.com

Abstract

Coronary artery disease (CAD) has become the leading cause of mortality in patients with Human Immunodeficiency Virus (HIV). The typical HIV-infected patient presenting with acute coronary syndrome (ACS) is a man in his mid to late 40s. The most common presentation is an acute myocardial infarction (MI), most often with ST segment elevation. Coronary anatomy seems to be variable, with some studies showing a higher prevalence of single-vessel disease and others showing a higher prevalence of 2- and 3-vessel disease than in controls not infected with HIV.

Keywords

Coronary Artery disease, Acute Coronary Syndrome, Human ImmunodeficiencyVirus, Antiretroviral therapy, Myocardial Infarction

Abbreviations

CAD: Coronary Artery Disease; HIV: Human Immunodeficiency Virus; MI: Myocardial Infarction; ART: Antiretroviral Therapy; ECG: Electrocardiography; STEMI: ST Elevation Myocardial Infarction; PCI: Percutaneous Coronary Intervention; SMART: Strategies for Management of Antiretroviral Therapy; ACS: Acute Coronary Syndrome; CABG: Coronary Artery Bypass Grafting

Introduction

Coronary artery disease (CAD) is the leading cause of mortality in patients infected with human immunodeficiencyvirus (HIV).[1] The pathophysiology of atherosclerosis in these patients is very complex, including direct endothelial damage from viremia, inflammation from immune activation, higher prevalence and contribution from traditional atherosclerotic risk factors, and direct effects from

antiretroviral therapy itself. [1] Recent reports on young HIV-infected patients have focused interest on the association between myocardial infarction (MI) and antiretroviral medications[2] It is not yet entirely clear whether there is a direct or indirect association between HIV infection or its treatment and acute coronary syndrome. It was found that although side effects of Antiretroviral therapy (ART) may contribute to some of the increased rate of CAD in patients with HIV; [3,4] untreated HIV infection is also associated with substantial increase in the risk of CAD. [5,6]

Case Presentation

We report a case of a 32 year old African American male who was previously healthy with no risk factors for coronary artery disease admitted to our hospital on account of a four week history of shortness of breath, fever and productive cough, his initial work up pointed toward atypical pneumonia that turned out to be pneumocystis jiroveci pneumonia. His HIV test came back as positive with a very low CD4 Count of 9 cells/mm³, his lipid panel was normal; he was started on 21 days course of Sulfamethoxazole/Trimethoprim. On the 12th day of admission the patient developed another episode of chest pain. Electrocardiography (ECG) showed new ST Elevation in the inferior leads (Figure-1) that was not evident on the original ECG on admission (Figure-2).

A diagnosis of acute ST elevation myocardial infarction (STEMI) was made and the patient was transferred immediately to the catheterization laboratory. Selective coronary angiography showed right dominant coronary system with acute thrombotic partial occlusion of the mid right coronary artery (Figure-3). The left main left anterior descending and circumflex arteries showed no signs of focal coronary artery disease. A coronary spasm was a consideration, however repeated doses of nitroglycerin did not change the RCA lesion. The patient underwent percutaneous coronary intervention (PCI) of the lesion using a drug-eluting stent. Post intervention images showed excellent results with no residual stenosis and TIMI 3 flow (Figure-4). Work-up for coagulopathy and potential thrombotic or embolic source did not establish any obvious source.

Patient was started on dual anti-platelet therapy, beta-blocker, and statin. Echocardiogram showed normal LV systolic function without wall motion abnormality or significant valvular abnormality.

Discussion

Evidence establishing the association between HIV and CAD comes from several epidemiologic data that show that HIV is associated with an increased risk of cardiac death, myocardial infarction (MI), and stable CAD. [5-10] This increased risk is seen earlier in HIV patients than in the general population. Currier et al compared the incidence of CAD among 28,513 HIV-infected individuals with 3,083,209

controls using data from California Medicaid (Medi-Cal) and found that the incidence of CAD among young men (<34 years) and women (<44 years) with HIV was significantly higher than controls. [7, 8] This suggests a potential acceleration of an atherogenic or thrombotic process in HIV-infected individuals even in relatively younger population.

HIV infection increases the risk of many risk factors of CAD. HIV has been associated with a significantly higher prevalence of CAD risk factors including hypertension (21.2% vs. 15.9%), diabetes (11.5% vs. 6.6%), and dyslipidemia (23.3% vs. 17.6%) than the non- HIV cohort ($P < 0.0001$ for each comparison). [9] In addition to the traditional risk factors, the risk of CAD in HIV patients seems to be linked to a CD4 count less than 500 cells/mm³. [10]

Although ART contributes to increased risk of CAD; [3,4] there is strong evidence that not being on ART therapy is a risk factor in itself. This evidence comes from the Strategies for Management of Antiretroviral Therapy (SMART) trial. [5] This study randomized 5472 HIV-positive patients with CD4 counts higher than 350 cells/mm³ on therapy to a management strategy of continuous ART versus intermittent use of ART depending on their CD4 counts. Participants in the intermittent arm would stop taking ARTs when their CD4 cell count reached greater than 350 cells/mm³ and restart therapy once the CD4 count reached 250 cells/mm³ or less. The intermittent therapy arm had a significant higher risk of nonfatal cardiovascular events (RR=1.5 with 95% 1.0–2.5). [6]

In another large population study, HIV infection was associated with significantly higher incidence of MI [11.13 per 1,000 vs. 6.98 per 1,000-patient years; Relative risk RR= 1.75 (95% CI, 1.51–2.02; $P < 0.0001$)]. This trend was even more significant among women. [9]. This risk of ACS could be related to increased thrombotic activity in these patients, evidenced by lower protein C level, higher factor VIII levels and higher frequencies of anticardiolipin and antiprothrombin antibodies when compared to non-HIV patients. [11] Another risk factor that may be responsible for the risk of MI is pneumonia; recent studies showed that the inflammatory state associated with pneumonia is associated with increased risk with cardiovascular events including MI. [12, 13]

The incidence of ACS in the HIV population trends to start in younger age and has some special characteristics. The typical HIV-infected patient presenting with ACS is a man in his mid to late 40s. The most common presentation is ST segment elevation MI. [6]. Coronary anatomy seems to be variable, with some studies showing a higher prevalence of single-vessel disease and others showing a higher prevalence of 2- and 3-vessel disease than controls not infected with HIV [6]. Compared to non-HIV patients, HIV-infected patients with a first episode of ACS had a higher incidence of recurrent ACS and

urgent PCI during the first year, this is increased risk of recurrent ACS is more linked to both increased risk of thrombosis and coronary restenosis. [14, 15]

The management of ACS in HIV patients is similar to its management in non-HIV patients. PCI with and without stenting as well as coronary artery bypass grafting(CABG) seems to be safe, effective and feasible option in HIV patients, but it is associated with a higher incidence of repeat revascularization in the long-term. [16-21]

Conclusion

HIV increases the risk of CAD especially in treatment naïve patients with low CD4 counts.

Management of CAD in these patients should be the same as for the general population, while keeping in mind that this group tends to have a higher incidence of recurrence especially in the first year.

Figures




Figure 1: ECG on day 12 of admission shows new ST Elevation MI in inferior leads II,III,aVF




Figure 2: ECG on admission, no signs of prior MI




Figure 3: Right Coronary Artery before intervention



Figure 4: Right Coronary Artery after intervention

References

1. Hakeem A, Bhatti S, Cilingiroglu M. The spectrum of atherosclerotic coronary artery disease in HIV patients. *Curr Atheroscler Rep.* 2010 Mar;12(2):119-24.
2. Rakhlin N, Hsue P, Cheitlin MD. Cardiac Manifestations of HIV. HIV InSite Knowledge Base Chapter. October 2005
3. Mary-Krause M1, Cotte L, Simon A, Partisani M, Costagliola D; Clinical Epidemiology Group from the French Hospital Database. Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. *AIDS* 2003;17: 2479–86.
4. Friis-Møller N, Sabin CA, Weber R, d'Arminio Monforte A, El-Sadr WM, Reiss Pet al. Combination antiretroviral therapy and the risk of myocardial infarction. *N Engl J Med* 2003;349:1993–2003.
5. El-Sadr WM, Lundgren J, Neaton JD, Gordin F, Abrams D, Arduino RC, et al. CD41 count-guided interruption of antiretroviral treatment. *N Engl J Med* 2006;355:2283–96.
6. Mishra RK. Cardiac emergencies in patients with HIV. *Emerg Med Clin North Am.* 2010 May;28(2):273-82.
7. Currier JS, Lundgren JD, Carr A, Klein D, Sabin CA, Sax PE, et al. Epidemiological evidence for cardiovascular disease in HIV-infected patients and relationship to highly active antiretroviral therapy. *Circulation* 2008, 118: e29–35.
8. Currier JS, Taylor A, Boyd F, Dezii CM, Kawabata H, BurtcelB, et al.: Coronary heart disease in HIV-infected individuals. *J Acquir Immune Defic Syndr* 2004, 33:506–512.
9. Triant VA, Lee H, Hadigan C, Grinspoon S. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. *J Clin Endocrinol Metab* 2007, 92:2506–2512.
10. Lichtenstein KA, Armon C, Buchacz K, Chmiel JS, Buckner K, Tedaldi EM, et al. HIV Outpatient Study (HOPS) Investigators. Low CD4+ T cell count is a risk factor for cardiovascular disease events in the HIV outpatient study. *Clin Infect Dis.* 2010 Aug 15;51(4):435-47.

11. Becker AC, Jacobson B, Singh S, Sliwa K, Stewart S, Libhaber E, et al. The Thrombotic Profile of Treatment-Naive HIV-Positive Black South Africans With Acute Coronary Syndromes. *ClinApplThrombHemost*. 2010 May 11.
12. Corrales-Medina VF, Alvarez KN, Weissfeld LA, Angus DC, Chirinos JA, Chang CC, et al. Association between hospitalization for pneumonia and subsequent risk of cardiovascular disease. *JAMA*. 2015 Jan 20;313(3):264-74.
13. Cangemi R, Casciaro M, Rossi E, Calvieri C, Bucci T, Calabrese CM, et al. Platelet activation is associated with myocardial infarction in patients with pneumonia. *J Am Coll Cardiol*. 2014 Nov 4;64(18):1917-25.
14. Boccara F, Mary-Krause M, Teiger E, Lang S, Lim P, Wahbi K, et al. Acute coronary syndrome in human immunodeficiency virus-infected patients: characteristics and 1 year prognosis. *Eur Heart J*. 2010 Oct 21.
15. Boccara F, Teiger E, Cohen A, Ederhy S, Janower S, Odi G, et al. Percutaneous coronary intervention in HIV infected patients: immediate results and long term prognosis. *Heart* 2006;92: 543-4
16. Hsue PY, Giri K, Erickson S, MacGregor JS, Younes N, Shergill A, et al. Clinical features of acute coronary syndromes in patients with human immunodeficiency virus infection. *Circulation* 2004;109:316-9.
17. Boccara F, Cohen A. Coronary artery disease and stroke in HIV-infected patients: prevention and pharmacological therapy. *Adv Cardiol* 2003;40:163-84.
18. Boccara F, Ederhy S, Janower S, Benyounes N, Odi G, Cohen A. Clinical characteristics and mid-term prognosis of acute coronary syndrome in HIV-infected patients on antiretroviral therapy. *HIV Med* 2005;6:240-4.
19. Matetzky S, Domingo M, Kar S, Noc M, Shah PK, Kaul S, et al. Acute myocardial infarction in human immunodeficiency virus-infected patients. *Arch Intern Med* 2003;163:457-60.
20. Boccara F, Teiger E, Cohen A, Ederhy S, Janower S, Odi G, et al. Percutaneous coronary intervention in HIV infected patients: immediate results and long term prognosis. *Heart* 2006;92: 543-4.
21. Boccara F, Cohen A, Di Angelantonio E, Meuleman C, Ederhy S, Dufaitre G, et al. Coronary artery bypass graft in HIV-infected patients: a multicenter case control study. *Curr HIV Res* 2008;6: 59-6.

Manuscript Information: Received: April 05, 2015; Accepted: April 28, 2015; Published: May 04, 2015

Authors Information: Zaher Fanari, MD; Sumaya Hammami, MD; Muhammad Baraa Hammami, MD; William S Weintraub, MD; Wasif A Qureshi, MD

¹Department of Cardiology, Christian Care Health System, Newark, Delaware, USA

²Texas Heart Institute, Houston, Texas, USA

Citation: Fanari Z et al. Acute coronary syndrome in HIV naïve Patient with low CD4 Count and no other significant risk factors: case report and literature review. *Open J Clin Med Case Rep*. 2015; 1009

Copy right Statement: Content published in the journal follows Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>). © Fanari Z et al

Journal: Open Journal of Clinical and Medical Case Reports is an international, open access, peer reviewed Journal mainly focused exclusively on the medical and clinical case reports.

Visit the journal website at www.jclinmedcasereports.com